Reagenzien und Instrumente für die Immunologie Zellbiologie und Molekularbiologie
 
> D-Lin-MC3-DMA [1224606-06-7]

D-Lin-MC3-DMA [1224606-06-7]

Drucken Drucken
Melden Sie sich an

Katalog-Nummer HY-112251-100mg

Size : 100mg

Marke : MedChemExpress

Contact local distributor :


Telefonnummer : +1 850 650 7790

D-Lin-MC3-DMA, an ionizable cationic lipid, is a potent siRNA delivery vehicle.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

D-Lin-MC3-DMA Chemische Struktur

D-Lin-MC3-DMA Chemische Struktur

CAS. Nr. : 1224606-06-7

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

D-Lin-MC3-DMA Related Antibodies

  • •Nat Nanotechnol. 2023 Jun 26.  [Abstract]
  • •ACS Nano. 2023 Jul 17.  [Abstract]
  • •ACS Nano. 2023 Jun 6.  [Abstract]
  • •Nat Commun. 2023 Jan 17;14(1):75.  [Abstract]
  • •Nat Commun. 2021 Dec 8;12(1):7101.  [Abstract]
  • •Sci Adv. 2021 Jan 13;7(3):eaba1028.  [Abstract]
  • •Proc Natl Acad Sci U S A. 2023 Aug 15;120(33):e2303567120.  [Abstract]
  • •J Biomed Sci. 2022 Dec 22;29(1):108.  [Abstract]
  • •J Microbiol Immunol Infect. 2023 Mar 8.
  • •Anal Chem. 2022 Jun 14.  [Abstract]
  • •Drug Deliv. 2023 Dec;30(1):2191891.  [Abstract]
  • •Drug Deliv. 2022 Dec;29(1):2644-2657.  [Abstract]
  • •Int J Pharm. 2023 Aug 24;123348.  [Abstract]
  • •Int J Pharm. 2023 Mar 25;122896.  [Abstract]
  • •Int J Pharm. 2021 Feb 25;599:120392.  [Abstract]
  • •Pharmaceutics. 2023 Mar 21;15(3):1009.  [Abstract]
  • •Pharmaceutics. 2022, 14(11): 2357.
  • •Pharmaceutics. 2022, 14(10), 2129.
  • •Pharmaceutics. 2021, 13(11), 1924.
  • •Mol Pharm. 2023 Jul 26.  [Abstract]
  • •Mol Pharm. 2023 Jul 18.  [Abstract]
  • •Mol Pharm. 2023 Mar 23.  [Abstract]
  • •Mol Ther Methods Clin Dev. 2023 May 11;29:450-459.  [Abstract]
  • •Mol Ther-Meth Clin D. 2023 May 11.
  • •Nanoscale Adv. 4th February 2022.
  • •Nucleic Acid Ther. 2023 Jun 30.  [Abstract]
  • •J Pharm Sci. 2022 Dec 31;S0022-3549(22)00617-7.  [Abstract]
  • •bioRxiv. 2023 Aug 14.
  • •OpenNano. 2023 May 8, 100161.
  • •Patent. US20230108926A1.
  • •Chemrxiv. Sep 29, 2022.
  • •Technischen Universität Dresden . Naturwissenschaftlich. 2022 Aug.
  • •bioRxiv. September 29, 2021.

  • Biologische Aktivität

  • Reinheit & Dokumentation

  • Verweise

  • Kundenbewertung

D-Lin-MC3-DMA, an ionizable cationic lipid, is a potent siRNA delivery vehicle.

In Vivo

Lipid nanoparticles (LNPs) containing distearoylphosphatidlycholine (DSPC), and ionizableamino-lipids such as dilinoleylmethyl-4-dimethylaminobutyrate (DLin-MC3-DMA) are potent siRNA delivery vehicles in vivo. LNP-siRNA systems optimize to achieve maximum gene silencing potency in hepatocytesfollowing IV administration in mice contain DLin-MC3-DMA (MC3), DSPC, cholesterol and a polyethyleneglycol (PEG)-lipid at mole ratios of 50/10/38.5/1.5. DLin-MC3-DMA exhibits an optimized pKa value that leads to dramatically enhanced potency.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

642.09

Liquid

C43H79NO2

1224606-06-7

O=C(OC(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCCCC/C=C\C/C=C\CCCCC)CCCN(C)C

Room temperature in continental US; may vary elsewhere.
In Vitro: 

Ethanol : 125 mg/mL (194.68 mM; Need ultrasonic)

DMSO : 100 mg/mL (155.74 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.5574 mL 7.7871 mL 15.5741 mL
5 mM 0.3115 mL 1.5574 mL 3.1148 mL
10 mM 0.1557 mL 0.7787 mL 1.5574 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    90% saline

    Solubility: 6.25 mg/mL (9.73 mM); Suspended solution; Need ultrasonic

  • 2.

    Add each solvent one by one:  5% DMSO    40% PEG300    5% Tween-80    50% saline

    Solubility: 5 mg/mL (7.79 mM); Suspended solution; Need ultrasonic

  • 3.

    Add each solvent one by one:  5% DMSO    95% (20% SBE-β-CD in saline)

    Solubility: 5 mg/mL (7.79 mM); Suspended solution; Need ultrasonic

  • 4.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (3.89 mM); Clear solution

  • 5.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (3.89 mM); Suspended solution; Need ultrasonic

  • 6.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.89 mM); Clear solution

  • 7.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.89 mM); Clear solution

*All of the co-solvents are available by MCE.

  • [1]. Kulkarni JA, et al. Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. Nanomedicine. 2017 May;13(4):1377-1387.  [Content Brief]

    [2]. Ferraresso F, Strilchuk AW, Juang LJ, Poole LG, Luyendyk JP, Kastrup CJ. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells. Mol Pharm. 2022;19(7):2175-2182.  [Content Brief]

  • [1]. Kulkarni JA, et al. Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. Nanomedicine. 2017 May;13(4):1377-1387.

    [2]. Ferraresso F, Strilchuk AW, Juang LJ, Poole LG, Luyendyk JP, Kastrup CJ. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA Delivery to Hepatocytes and Hepatic Stellate Cells. Mol Pharm. 2022;19(7):2175-2182.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Metabolic Enzyme/Protease
  • Liposome
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Sie könnten auch an folgenden Produkten interessiert sein:



Katalog-Nummer
Beschreibung
Cond.
Preis zzgl. MwSt.